Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

I-Mab Acquires China Rights to I-O mAb from MorphoSys in $105 Million Deal

publication date: Nov 16, 2018

I-Mab Biopharma of Tianjin in-licensed greater China rights to a novel checkpoint inhibitor from Germany's MorphoSys in a $105 million agreement. I-Mab will also conduct proof-of-concept clinical studies of MOR210, a preclinical C5aR antibody. In return for the proof-of-concept studies, MorphoSys will pay I-Mab single digit royalties on any revenues outside greater China. One year ago, I-Mab in-licensed rights to a MorphoSys anti-CD38 mAb in a $120 million deal. More details....

Stock Symbols: (FSE/NSDQ: MOR)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.